Researchers Say Seven To Nine Percent Of Patients With Advanced Cancer May Harbor Germline Variant With Targeted Therapeutic Actionability

Medscape (6/2, Nelson, Subscription Publication) reports researchers found “from 7% to nearly 9% of patients with advanced cancer were found to harbor a germline variant with targeted therapeutic actionability in the first study of its kind.” The findings...